Medtronic backs Pulnovo Medical in $100m round to expand PADN in pulmonary hypertension
Pulnovo Medical raised $100 million with Medtronic backing. Read what it means for PADN, pulmonary hypertension, heart failure, and device markets.
Can Merck expand WINREVAIR beyond pulmonary arterial hypertension after CADENCE data?
Can Merck turn WINREVAIR’s CADENCE data into a new treatment path in CpcPH-HFpEF? Read the full analysis of what changes next.
Why WINREVAIR’s Phase 2 data matters beyond pulmonary arterial hypertension
CADENCE trial data shows sotatercept’s promise in HFpEF-linked pulmonary hypertension. Find out what this means for treatment and regulation.
What Anumana’s FDA-cleared pulmonary hypertension algorithm means for cardiovascular AI
Anumana won FDA clearance for an ECG-AI pulmonary hypertension tool. Read what it changes for diagnosis, workflow adoption, and cardiovascular AI strategy.
CorVista Health expands machine-learning diagnostics to INOCA with new ACC.26 poster data
CorVista Health presents machine-learned non-invasive INOCA detection data at ACC.26. Analysis of what this means for cardiology and women’s heart care. Read more.
United Therapeutics targets 2026 FDA submission for Tyvaso IPF indication after TETON-2 success
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
GSK plc and 35Pharma Inc.: what the $950m HS235 deal changes in pulmonary hypertension therapy
GSK is acquiring 35Pharma for $950 million to strengthen its pulmonary hypertension pipeline. Find out what HS235 changes and what risks remain.